BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival

(2016) Hiroto Ohguchi et al.   Nature Communications

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

(2015) Thomas Cluzeau et al.   Oncotarget

Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity

(2014) R. W. Rooswinkel et al.   BLOOD

Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B

(2013) B van de Kooij et al.   ONCOGENE

Bim regulates B-cell receptor-mediated apoptosis in the presence of CD40 signaling in CD40-pre-activated splenic B cells differentiating into plasma cells

(2012) Yuanyuan Gao et al.   INTERNATIONAL IMMUNOLOGY

Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1

(2012) L. J. Beverly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist

(2012) G J P Rautureau et al.   Cell Death & Disease

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23)

(2011) Naoki Morito et al.   CANCER RESEARCH

Osteoclast activity modulates B-cell development in the bone marrow

(2011) Anna Mansour et al.   CELL RESEARCH

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

(2010) H. Ludwig et al.   ONCOLOGIST

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

(2009) Anne Catherine Sprynski et al.   BLOOD

The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma

(2009) Mathilde Romagnoli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7

(2009) N. D. Huntington et al.   INTERNATIONAL IMMUNOLOGY

MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

(2009) L J Beverly et al.   ONCOGENE

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies

(2008) M. Krajewska et al.   CLINICAL CANCER RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE